Document is current
Any future updates will be listed below
-
Authors
Liu, Yiran E.
Saul, Sirle
Rao, Aditya Manohar
Robinson, Makeda Lucretia
Agudelo Rojas, Olga Lucia
Sanz, Ana Maria
Verghese, Michelle
Solis, Daniel
Sibai, Mamdouh
Huang, Chun Hong
Sahoo, Malaya Kumar
Gelvez, Rosa Margarita
Bueno, Nathalia
Estupiñan Cardenas, Maria Isabel
Villar Centeno, Luis Angel
Rojas Garrido, Elsa Marina
Rosso, Fernando
Donato, Michele
Pinsky, Benjamin A.
Einav, Shirit
Khatri, Purvesh https://orcid.org/0000-0002-4143-4708
-
Funding
Funding for this research was provided by:
Dr. Ralph and Marian Falk Medical Research Trust
U.S. Department of Defense (W81XWH1910235)
SPARK at Stanford
Stanford Bio-X
National Institute of Allergy and Infectious Diseases (1U19AI109662, U19AI057229)
Bill and Melinda Gates Foundation (OPP1113682)
- License Information
-
More Information
Article History
Received: 23 October 2021
Accepted: 24 February 2022
First Online: 29 March 2022
Declarations
:
: This study conformed to the principles of the Helsinki Declaration and was approved by the Stanford University Administrative Panel on Human Subjects in Medical Research (protocols #35460 and #50513) and the ethics committees in biomedical research of the Fundación Valle del Lili (FVL, Cali, Colombia) and Centro de Atención y Diagnóstico de Enfermedades Infecciosas (CDI, Bucaramanga, Colombia). All subjects or their parents or legal guardians provided written informed consent, and subjects between 2 and 17 years of age and older provided assent.
: Not applicable.
: BAP reports Scientific Advisory Board membership for Globavir, outside the submitted work; in addition, BAP has a patent US 9725774 B2 licensed to Globavir. PK reports personal fees from Inflammatix, Inc., Cepheid, Inc., Vir Biotechnology, and Genentech, outside the submitted work. The 8-gene set has been disclosed for possible patent protection to the Stanford Office of Technology and Licensing by YEL, SE, and PK. The remaining authors declare that they have no competing interests.
